Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models

Sunday, 07 February 2010 17:34

Marketwire

GENEVA, SWITZERLAND--(Marketwire - February 8, 2010) -

Addex Pharmaceuticals / Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed nd transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain.

Inthe firstmodel, ADX71943reversed completeFreund adjuvant (CFA)- induced reductionsin withdrawalthresholds ina dose-relatedmanner, with a minimum statisticallysignificant effectiveoral doseof 10 mg/kg.In a second model (Formalin test), ADX71943 showed anti-nociceptive effect after oral administrationof 3 to 10 mg/kg.In a thirdmodel, an increased visceral pain thresholdwasseenusingADX71943witha minimum statistically significant effective dose between 3 and 10 mg/kg.

ADX71943isanorallyavailablepositiveallosteric modulator (PAM) of the GABA(B)receptor thathas potentialfor treatmentof osteoarthritis pain and chronicnociceptivepainaswellasother indications. ADX71943 has a good developabilityprofile and is expected toenter clinical testing in the fourth quarter 2010.

"We are impressed with the profile of the compound and by its activity in these models. Furthermore, minimum effective doses observed in thepreclinicalmodelsand the pharmacokineticpropertiesofthecompoundsupportprediction of treatment regimensin humans compatiblewith the targetpatient population and disease" said Sonia Poli, head of non-clinical development at Addex.

GABA(B)activationisaclinicallyvalidated mechanism. Baclofen, a GABA(B) agonist,is widely usedfor its musclerelaxant properties inthe control of spasticitycaused by multiple sclerosis, cerebralpalsy or certain injuries to thespine. Furthermore, Baclofen is a powerful analgesic agent, especially when delivered intrathecally. However, rapid induction of tolerance and dose limiting CNS-mediatedsideeffects(e.g.sedation,hypothermia,memory impairment) preventbaclofenfrombeingwidelyprescribedforpain relief despite its analgesicproperties. ADX71943,an allostericmodulator with a differentiated profile,couldavoidthetoleranceanddose limiting side effects commonly associated with baclofen.

Osteoarthritis(OA) is a widespreadcondition affecting the elderly population inparticular. One of the most debilitating symptoms is chronic pain associated withOA. Patients sufferingfrom chronic painwill require treatment over the long-term. There is a clear need for drugs with better side effect profiles than current marketed drugs (e.g. non-steroidal anti-inflammatory drugs and opioids).

AddexPharmaceuticals (www.addexpharma.com) utilizesits unique proprietaryplatform technologies todiscover and develop allostericmodulators for humanhealth. Allosteric modulatorsare a different kind of orally available small molecule therapeutic agent, which we believe will offeracompetitiveadvantageoverclassicaldrugs.With15 programsin development, theAddexpipelinedemonstratestheproductivityand broad potentialof our unparalleled platform technologies. The most advanced product, ADX48621,an mGluR5 negative allosteric modulator(NAM), has completed Phase I testingandisscheduledtostartPhase II testing for Parkinson's disease levodopa associated dyskinesia (PD-LID) later in 2010.

Ourproductsandtechnologyalreadyhaveproventheirvalue through our relationshipswith fourof thetop 10 pharmaceuticalcompanies in the world. Specifically,underanagreementwithOrtho-McNeil-JanssenInc., a Johnson & Johnsoncompany, ADX71149,an mGluR2positive allostericmodulator (PAM), is undergoingPhaseIclinicaltestingandhaspotentialfor treatmentof schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc., wearedevelopingPAMsofmGluR4andmGluR5 as drugs to treat Parkinson's diseaseandschizophrenia,respectively.Inaddition, SR-One, the corporate venturearmofGlaxoSmithKline,andRocheVentureFundhavemade equity investments in Addex.

Chris Maggos Investor Relations & Communications Addex Pharmaceuticals +41 22 884 15 11 This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Disclaimer:The foregoing release containsforward-looking statements that can beidentified by terminology suchas "not approvable", "continue", "believes", "believe","will", "remained opento exploring", "would","could", or similar expressions, or by express or implied discussions regarding Addex PharmaceuticalsLtd, itsbusiness, thepotential approvalof its products by regulatoryauthorities,orregardingpotentialfuturerevenuesfrom such products.Such forward-lookingstatements reflectthe currentviews of Addex PharmaceuticalsLtdregardingfutureevents,andinvolve known and unknown risks,uncertaintiesandotherfactorsthatmaycause actual results with allostericmodulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to bematerially differentfrom anyfuture results,performance or achievements expressedorimpliedbysuchstatements.Therecanbeno guarantee that allostericmodulators of mGluR4, mGluR2 or mGluR5will be approved for sale in anymarketorbyanyregulatoryauthority.Nor can there be any guarantee that allostericmodulatorsofmGluR4,mGluR2,mGluR5orother therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management'sexpectationsregarding allosteric modulatorsof mGluR4,mGluR2, mGluR5 or other therapeutic targets could be affected by, among otherthings, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, includingunexpected newclinical dataand unexpectedadditional analysis of existing clinical data; competition in general; government, industry and general publicpricing pressures; the company's ability to obtain or maintain patent or otherproprietary intellectual property protection. Should one or more of these risksoruncertaintiesmaterialize,orshouldunderlying assumptions prove incorrect,actual results may vary materially from those anticipated, believed, estimatedor expected.Addex Pharmaceuticalsis providingthe information in thispress releaseas ofthis dateand doesnot undertake any obligation to updateanyforward-lookingstatementscontainedinthis press release as a result of new information, future events or otherwise.

[HUG#1381443]

Francais (pdf): http://hugin.info/138017/R/1381443/340695.pdf

English (pdf): http://hugin.info/138017/R/1381443/340694.pdf

Deutsch (pdf): http://hugin.info/138017/R/1381443/340696.pdf

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section

Add this page to your favorite Social Bookmarking websites